Caribou Biosciences announced that it will present oral updates on its vispa-cel and CB-011 CAR-T cell therapies at the 2026 European Hematology Association Annual Meeting in June. Vispa-cel, targeting relapsed/refractory B cell non-Hodgkin lymphoma, and CB-011, for relapsed/refractory multiple myeloma, are both innovative allogeneic CAR-T therapies with unique genome-editing features designed to enhance efficacy and reduce immune rejection. These presentations will share long-term and follow-up clinical trial data, highlighting progress in these treatments. This event marks a key opportunity for Caribou to showcase advancements and regulatory progress, including FDA designations for both therapies.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
Standard Chartered has partnered with Broadcom to modernize its global banking infrastructure by adopting a secure, resilient private cloud using VMware Cloud Foundation. This upgrade supports critical banking services across 54 markets with enhanced...
